To clarify the risk factors for developing microalbuminuria in patients with type 2 diabetes mellitus, a longitudinal observational study was performed. Fifty patients with normoalbuminuria were recruited and treated conventionally for 9 years. Polymorphisms of the angiotensinconverting enzyme (ACE) gene and the angiotensinogen M235T polymorphism were examined. During the study period, 12 of the 50 patients developed microalbuminuria; no patients progressed to macroalbuminuria. Multiple logistic regression analysis was performed using age, duration of diabetes, body mass index, haemoglobin A 1c , blood pressure, serum lipid profile and genetic polymorphisms as independent variables and development of microalbuminuria as the dependent variable. The D allele of the ACE gene was an independent and significant variable. We conclude that the ACE gene D allele polymorphism is a potent risk factor for developing microalbuminuria in type 2 diabetic patients.
Introduction
Diabetic nephropathy is a major cause of morbidity and mortality in both type 1 and type 2 diabetes mellitus patients. 1,2 A number of reports have indicated that multiple risk factors, including metabolic control, 3,4 haemodynamic status 5,6 and duration of diabetes are involved in the development and progression of diabetic nephropathy. Genetic factors have also been implicated as potent risk factors for diabetic nephropathy, since its occurrence clusters within families in both type 1 and type 2 diabetes. 7,8 Angiotensin-converting enzyme (ACE) gene polymorphisms have been extensively studied in both types of diabetes. 9 - 18 We and others have reported that the D (deletion) allele of the ACE gene was significantly associated with diabetic nephropathy 9 -11 following cross-sectional analysis, whereas others have reported no association between ACE gene polymorphisms and disease. 13 -18 It is still unclear whether this discrepancy is based on ethnic differences, metabolic or haemodynamic status, or methodological issues.
We now report on a longitudinal study performed to investigate whether the D allele of the ACE gene is an independent risk factor for developing microalbuminuria in patients with metabolically controlled type 2 diabetes.
Patients and methods

PATIENTS
Elderly patients with type 2 diabetes, who were normoalbuminuric in 1990, were recruited to the study and treated conventionally for 9 years. Patients developing microalbuminuria due to other diseases such as congestive heart failure, glomerulonephritis or urinary tract infection during the 9-year study period were excluded. Patients with diabetes of less than 5 years' duration in 1990 were also excluded. All patients gave informed consent.
Age, sex and duration of diabetes in 1990 were recorded. Baseline values (in 1990 ) and values at the end of the 9-year study period (in 1999) for body mass index (BMI), haemoglobin A 1c (HbA 1c ), systolic and diastolic blood pressure, total cholesterol, triglyceride and highdensity lipoprotein-cholesterol levels were obtained, together with information concerning the presence of hypertension, retinopathy and nephropathy at the two time points.
All patients visited our clinic every month during the period studied and were treated conventionally with the aim of maintaining HbA 1c at < 7.0% and blood pressure at < 140/90 mmHg.
Haemoglobin A 1c levels were measured using high-performance liquid chromatography. Serum concentrations of total cholesterol, triglycerides and high-density lipoprotein-cholesterol were measured using standard laboratory methods.
Hypertension was defined as a mean systolic blood pressure > 140 mmHg and mean diastolic blood pressure > 90 mmHg, or as being in receipt of oral anti-hypertensive agents.
Patients were assessed by two independent opthalmologists using ophthalmoscopic examination, with evidence of retinopathy graded as non-diabetic retinopathy, simple diabetic retinopathy, pre-proliferative diabetic retinopathy or proliferative diabetic retinopathy according to the diagnostic classification of Davis et al. 19 Nephropathy was assessed by measuring the urinary concentration of albumin, by radioimmunoassay. The urinary albumin excretion rate (UAER) was calculated using timed overnight urine samples. A UAER < 10 µg/min, UAER between 10 µg/min and 200 µg/min and UAER > 200 µg/min were classified as normoalbuminuria, microalbuminuria and macroalbuminuria, respectively. 20 The UAER was measured at least three times a year. No patients underwent renal biopsy.
GENE ANALYSIS
Angiotensin-converting enzyme gene analysis was performed during the study as previously described. 11 Briefly, DNA was isolated from the patients' peripheral blood and amplified by polymerase chain reaction (PCR) using primers specific for the ACE gene (5′-CTGGAGACCACTCCCATCCTTTCT-3′ and 5′-GATGTGGCCATCACATTCGTCAGAT-3′). The angiotensinogen (AGT) M235T polymorphism was also analysed by PCR using primers specific for the AGT gene (5′-GATGCGCACAAGGTCCTG-3′ and 5′-CAGGGTGCTGTCCACACTGGCTCGC-3′). After amplification, each product was digested with the restriction enzyme SfaNI, separated by electrophoresis through a 4% agarose gel, and visualized using ethidium bromide staining as previously described. 11
STATISTICAL ANALYSIS
Results are presented as the mean ± SD, median (and range), or prevalence (%). Data were analysed using SPSS  statistical software (SPSS Inc., Chicago, Illinois, USA). Comparisons between the two groups were performed using Student's t-test or the Mann-Whitney U-test.
For multiple comparisons, one-way analysis of variance (ANOVA) followed by Fisher's protected least significant difference test was used. Fisher's exact test and the χ 2 test were used to compare groups of discrete variables. To clarify the risk factors for developing microalbuminuria, a multiple logistic regression test was performed using age, duration of diabetes, BMI, HbA 1c , systolic and diastolic pressure, serum lipid profile, and ACE D allele and AGT M235T gene polymorphisms as independent variables, and development of microalbuminuria as the dependent variable. A P-value of < 0.05 was considered significant.
Results
A total of 53 patients were recruited to the study, but three were later excluded because they were lost to follow-up. Fifty patients (24 men and 26 women) completed the study, and in 1990 had an average age (± SD) of 60.8 ± 13.2 years (range 24 -77 years), a duration of diabetes of 11.6 ± 6.3 years (range 5 -27 years) and a BMI of 22.3 ± 3.5 (range 15.6 -27.7). Of these 50 patients, 12 had developed microalbuminuria by the end of the 9-year period studied. No patients had developed macroalbuminuria. Patients were divided into two groups on the basis of the UAER at the end of 1999: those with normoalbuminuria and those who had developed microalbuminuria. Table 1 shows the clinical characteristics of the subjects at baseline and after 9 years. The baseline values for age, sex, duration of diabetes, BMI, HbA 1c , systolic and diastolic pressure and serum lipid profile were not significantly different in subjects with normoalbuminuria after 9 years compared with those with microalbuminuria. The BMI, blood glucose levels, lipid profiles and blood pressure at baseline were not significantly different in either group of subjects from those recorded after 9 years.
Ten of the 24 hypertensive subjects with normoalbuminuria and two of the six hypertensive subjects with microalbuminuria had been receiving antihypertensive agents since 1990. Six subjects with normoalbuminuria and two subjects with microalbuminuria started taking an ACE inhibitor or an angiotensin II receptor antagonist during the study period.
Angiotensin-converting enzyme and AGT genotypes were determined in all patients and are shown in Table 2 with the allele frequencies. The difference in frequencies between the groups with micro-and normoalbuminuria was statistically significant (P = 0.017). The frequency of the D allele of the ACE gene in subjects who developed microalbuminuria was significantly higher than in subjects with normoalbuminuria (P < 0.0001). By contrast, there were no significant associations between the incidence of diabetic nephropathy and AGT gene M235T polymorphism (Table 2) .
To assess whether the D allele of the ACE gene is a risk factor for developing S Okuno, T Utsugi, T Ohno et al. ACE gene polymorphism and microalbuminuria in diabetes microalbuminuria, multiple logistic regression analysis was performed using age, duration of diabetes, baseline BMI, HbA 1c , blood pressure and serum lipid levels, presence of the D allele of the ACE gene and presence of the AGT M235T polymorphism as independent variables and development of microalbuminuria as a dependent variable. The odds ratio and 95% confidence intervals for the variables are shown in Table 3 . None of the clinical variables at baseline were significantly associated with development of microalbuminuria. In contrast, the D allele of the ACE gene was found to be an independent and significant variable (Table 3) .
To determine whether the clinical features of patients with the DD (deletion/deletion) or the ID (insertion/deletion) ACE genotypes are different from those with the II (insertion/insertion) genotype, patient characteristics were compared in the different genotype groups (Table 4 ). There 
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was no significant difference with respect to sex, age, duration of diabetes, BMI, HbA 1c , blood pressure or serum lipid profile among the three ACE genotypes.
Discussion
In this 9-year longitudinal study, we have shown that the D allele of the ACE gene is associated with the development of microalbuminuria in Japanese patients with type 2 diabetes mellitus.
The ACE gene polymorphism has been extensively studied as one of the genetic risk factors for diabetic nephropathy, 9 -18 but several studies have yielded conflicting results. An initial study showed an effect of the ACE genotype in insulin-dependent diabetes mellitus patients. 12 Subsequent studies from our laboratory 11 and others 9,10 have also indicated a significant association (P < 0.01) between the ACE genotype and diabetic nephropathy. In contrast, several reports have shown no association between the ACE genotype and diabetic nephropathy, either in type 1 or type 2 diabetes mellitus. 13 -18 There are several possible reasons for these discrepancies:
First, the association may be affected by ethnic differences. A meta-analysis study 
S Okuno, T Utsugi, T Ohno et al. ACE gene polymorphism and microalbuminuria in diabetes
demonstrated that reports from East Asian countries such as Japan and Korea have shown a significant association between the ACE genotype and diabetic nephropathy, whereas some studies from European countries have reported no association. 21 In contrast, a recent study from Italy using morphometric analysis of kidney biopsies did demonstrate an association. 22 The reasons for these possible ethnic differences are still undetermined.
Secondly, the effects of study design need to be taken into consideration. Most of the previous studies are cross-sectional or retrospective studies, and results need to be confirmed by a prospective cohort study. Some prospective studies have been reported from Europe and Japan. Huang et al. 23 reported that the ACE ID polymorphism was not associated with diabetic nephropathy in non-insulin dependent diabetes mellitus patients during a 9-year follow-up study. In contrast, Oue et al. 24 reported in a 10-year follow-up study that in addition to age and HbA 1c , the ACE ID polymorphism was associated with the progression of microalbuminuria. Our results are consistent with the data reported by Oue et al. 24 We did not demonstrate an association between glycaemic or haemodynamic status and nephropathy in our study, but this may be due to the fairly good control of blood glucose levels and blood pressure achieved throughout the study period. Our recent study 25 showed that blood pressure is the most important risk factor for the development of macroalbuminuria in type 2 diabetes patients who have already had microalbuminuria.
Thirdly, the use of urinary albumin to assess diabetic nephropathy can lead to discrepancies. Microalbuminuria, caused by diseases other than diabetes (such as congestive heart failure, glomerulonephritis or urinary tract infection), or resulting from physical exercise, can occur in patients with diabetes. We excluded these The role of the D allele of the ACE gene in the development of diabetic nephropathy is still undetermined, although plasma ACE activity in subjects with the D allele has been shown to be higher than in subjects without the D allele. 20, 26, 27 In the present study, the odds ratio of the ACE gene polymorphism was relatively high compared with those estimated from several meta-analyses. One possible explanation for this is the small number of subjects. Another is that the contributions of blood glucose levels and blood pressure were relatively weak, since metabolic and haemodynamic control were fairly good throughout this study.
In conclusion, the D allele of the ACE gene polymorphism appears to be a major risk factor for developing microalbuminuria in Japanese patients with type 2 diabetes mellitus. Values given are number of patients or mean ± SD. No significant differences on one-way analysis of variance were found between the three ACE genotypes.
